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Bilateral upper extremity motor priming
(BUMP) plus task‑specific training for severe,
chronic upper limb hemiparesis: study protocol
for a randomized clinical trial
Mary Ellen Stoykov1,2* , Olivia M. Biller3, Alexandra Wax1,4, Erin King5, Jacob M. Schauer6, Louis F. Fogg7 and
Daniel M. Corcos8

Abstract
Background: Various priming techniques to enhance neuroplasticity have been examined in stroke rehabilitation
research. Most priming techniques are costly and approved only for research. Here, we describe a priming technique
that is cost-effective and has potential to significantly change clinical practice. Bilateral motor priming uses the
Exsurgo priming device (Exsurgo Rehabilitation, Auckland, NZ) so that the less affected limb drives the more affected
limb in bilateral symmetrical wrist flexion and extension. The aim of this study is to determine the effects of a 5-week
protocol of bilateral motor priming in combination with task-specific training on motor impairment of the affected
limb, bimanual motor function, and interhemispheric inhibition in moderate to severely impaired people with stroke.
Methods: Seventy-six participants will be randomized to receive either 15, 2-h sessions, 3 times per week for 5 weeks
(30 h of intervention) of bilateral motor priming and task-specific training (experimental group) or the same dose of
control priming plus the task-specific training protocol. The experimental group performs bilateral symmetrical arm
movements via the Exsurgo priming device which allows both wrists to move in rhythmic, symmetrical wrist flexion
and extension for 15 min. The goal is one cycle (wrist flexion and wrist extension) per second. The control priming
group receives transcutaneous electrical stimulation below sensory threshold for 15 min prior to the same 45 min of
task-specific training. Outcome measures are collected at pre-intervention, post-intervention, and follow-up (8 weeks
post-intervention). The primary outcome measure is the Fugl-Meyer Test of Upper Extremity Function. The secondary
outcome is the Chedoke Arm and Hand Activity Index-Nine, an assessment of bimanual functional tasks.
Discussion: To date, there are only 6 studies documenting the efficacy of priming using bilateral movements, 4 of
which are pilot or feasibility studies. This is the first large-scale clinical trial of bilateral priming plus task-specific training. We have previously completed a feasibility intervention study of bilateral motor priming plus task-specific training
and have considerable experience using this protocol.
Trial registration: ClinicalTrials.gov NCT03517657. Retrospectively registered on May 7, 2018.
Keywords: Chronic stroke, Priming, Task-specific training, Transcranial magnetic stimulation, Upper limb
rehabilitation
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Introduction
Background and rationale {6a}

The decline in stroke mortality over the twentieth century [1] has increased incidence of post-stroke disability,
and the most common disability in the stroke population
is upper extremity (UE) hemiparesis. Constraint-induced
movement therapy (CIMT) is an effective intervention
but is only appropriate for stroke survivors with mild
UE impairment who are in the upper quartile of residual
function [2]. Thus, alternative treatments are needed to
target stroke survivors with more moderate and severe
impairments of the UE, whose prognosis for motor
recovery is less favorable.
In an observational study, Ward and colleagues [3]
demonstrated a large improvement in the Fugl-Meyer
Test of Upper Extremity Function (FMUE) median score
(FMUEΔ 8.0, IQR=4–11) in severely impaired individuals after 90 h of various types of occupational therapy.
While the improvement was impressive, the study did
not inform about the superiority of any specific training. Also, 90 h of training is a very large dose that is not
sustainable in the current healthcare climate in the USA.
Other studies using unilateral training for individuals
with severe UE impairment have shown improvements
that can be described as modest at best including robotic
training (FMUEΔ = 1.11 ± 1.01) [4]; unilateral taskspecific training in an active comparator group (FMUEΔ
= 3.1 ± 5.3) [5]; and task-specific training + robotics
(FMUEΔ = +3.25 ± 1.68) [6]. These studies did not demonstrate an improvement in the FMUE of ≥ 4.25 which
is the estimated clinically important difference [7]. More
impaired individuals may need either a larger dose or an
augmentative intervention.
Motor priming is a construct used to describe a variety of techniques that optimize the brain’s response to
subsequent training and may enhance neuroplasticity
and motor performance [8–10]. Shiner et al. [11] compared bilateral motor priming (BMP) plus Wii therapy
to Wii therapy alone in subacute and chronic stroke subjects. The result was in favor of the bilateral priming plus
Wii training group that, at follow-up, had a significantly
greater mean FMUE [12] score than with Wii training
alone (6.3 between-group difference) [11]. There was a
large range of impairment levels in the Shiner et al. study,
and those individuals with more severe impairment had
the largest improvement. This result suggests that BMP
may magnify improvements inherent in therapy protocols and facilitate sustained improvements over time in
individuals with severe UE impairment. Stoykov and colleagues [13] used a task-specific training (TST) protocol
and combined it with either BMP or stroke education
(control). The bilateral priming group had a substantial increase in FMUE scores from pre-intervention to
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follow-up (FMUEΔ = 10 ± 6.1) while the improvement
in the control group was modest (FMUEΔ = 3.56 ±
4.1.) These data were used as the pilot data for the grant
submission.
Another priming + TST study examining UE hemiparesis in severely impaired participants used sensorybased priming plus TST [14] compared to TST alone, and
the between-group differential of the FMUE was highest
at follow-up (between-group FMUEΔ was 4.4 ± 1.1).
This finding is consistent with other studies confirming
that the largest difference between priming and control
group is at follow-up [13–18].
This clinical trial examines the use of BMP, a non-invasive, cost-effective neuromodulation technique. BMP
consists of continuous, bilateral wrist flexion and extension using a device with a mechanical linkage so that the
less affected hand and the more affected one move in
symmetry [19]. This study is a pivotal step towards developing and using a practical neuromodulatory technique
to prime the central nervous system to respond with
greater efficacy to behavioral interventions for people
with moderate to severe UE hemiparesis. In addition to
the benefits mentioned above and compared to priming
using more invasive methods such as repetitive transcranial magnetic stimulation (rTMS), BMP is (1) cost-effective; (2) available to a larger pool of people due to the
absence of safety concerns; (3) does not require a skilled
operator; and (4) can potentially be implemented into the
clinic [20]. There are no known risks to bilateral priming.
Objectives {7}

The purpose of this study is to test the hypothesis that
bilateral symmetrical arm movements prime cortical regions and enhance neuroplasticity as measured by
behavioral and cortical measures. Specifically, this trial
will address two main objectives and test their associated
hypotheses. The primary objective is to determine the
magnitude of change in upper limb function and impairment in chronic stroke survivors who have undergone
30 h of BMP + TST. Primary hypothesis 1.1 is that the
combination of BMP + TST will produce a betweengroup difference in improvement on the FMUE of at least
6.0 points more than control priming (CP) + TST at the
follow-up timepoint (8 weeks post-treatment cessation).
Secondary hypothesis 1.2 is that the combination of BMP
+ TST will increase scores on the Chedoke Arm & Hand
Activity Index (CAHAI-9) by 3 points more than CP +
TST, 8 weeks after the post-test (follow-up).
The secondary objective is to determine the effects of
bilateral priming on cortical mechanisms measured by
TMS. Hypothesis 2.1 is that BMP + TST will increase
TCI from ipsilesional to contralesional hemisphere at
post-treatment (following 30 h of treatment) and at 8
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weeks after treatment cessation (follow-up), but there
will be no change in the CP + TST group. Hypothesis 2.2
is that an increase in ipsilesional TCI will be positively
associated with changes in the FMUE. We will perform a
correlation analysis to test this relationship.
Trial design {8}

This protocol adheres to the guidance of the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) statement for reporting randomized
clinical trials [21]. The study design is a stratified, randomized, masked, and parallel, two-arm intervention
study of the effects of BMP and TST. This is a two-site
superiority trial.

Methods: participants, interventions,
and outcomes
Study setting {9}

Assessments are performed at the Northwestern University Department of Physical Therapy and Human
Movement Science (PTHMS). Prior to the COVID19 pandemic, treatment intervention and some of the
assessments occurred at the Shirley Ryan AbilityLab.
Northwestern University human subjects’ research was
closed in March of 2020. Research resumed in July of
2020 but with significant restrictions specifying number of participants per research lab and strict adherence
to protective equipment for both investigators and participants. Due to these restrictions, and preferences of
the study team, the investigators decided to use both the
Northwestern PTHMS Department and Shirley Ryan
AbilityLab for treatment. Assessments are now only
performed at Northwestern PTHMS Department. Both
locations are in Chicago, Illinois.
Eligibility criteria {10}

Inclusion and exclusion criteria can be found in Table 1.
Eligibility criteria for clinicians working as standardized treatment therapists for this trial include being a registered and licensed occupational therapist. Assessments
are performed by licensed occupational therapists who
are not treating the participants. Research staff trained
in TMS, collect the TMS data. A TMS safety checklist is
administered to ensure no contraindications to TMS.
Who will take informed consent? {26a}

If a participant is found to be eligible and wants to be
in the study, informed consent is obtained by a research
team member during the in-person screen. A model
consent form is attached as an Additional file (see Additional file 2). The research is conducted in compliance
with state and federal laws, including the Health Insurance Portability and Accountability Act (HIPAA) which
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Table 1 Inclusion and exclusion criteria
Inclusion criteria

Exclusion criteria

(a) Evidence of a stroke without involvement of the cerebellum at least 6 months (a) Orthopedic conditions of either the less affected or affected wrist
prior to enrollment
(b) FMUE score between 23 and 38

(b) An MMSE score lower than 21

(c) 0 through 3 in wrist flexion and wrist extension on the Modified Ashworth
Scale

(c) A stroke in the cerebellum

(d) Individuals who are at least 18 years old and have the ability to consent.

(d) History of epilepsy, seizures, or convulsions
(e) Ringing in ears
(f ) Presence of cochlear implant
(g) Presence of pacemaker or neurostimulator
(h) History of persistent headaches
(i) Metal implant or fragments of metal in head or neck area
(j) Presence of other neurological conditions including PD or CP
(k) History of head trauma or concussion with loss of consciousness
(l) Received Botox in the affected UE within the past 6 months
(m) Metastatic cancer
(n) Prisoners, children, or pregnant women
(o) Individuals under the age of 18
(p) Any adult unable to consent

requires researchers to protect and maintain confidentiality of an individual’s health information. All subjects
are asked to sign an “Authorization to Use and Disclose
(Release) Health Information for a Research Study.”
All research staff are trained in proper procedures for
obtaining informed consent.
Study staff complete all initial phone screens, in-person
screens, and consenting of participants. “SOP: Informed
Consent Process for Research (HRP-090)” is followed
while obtaining consent from each individual participant.
Additional consent provisions for collection and use
of participant data and biological specimens {26b}

If the participant agrees, we collect videos of the participant performing functional tasks pre- and post-intervention. Videos are used to train therapists in the study
protocol as well as demonstrate functional improvement during academic and scholarly presentations. The
choice to videotape is clearly stated on the consent form.
The participant has the right not to be videotaped. This
trial does not involve collecting biological specimens for
storage.

Interventions
Explanation for the choice of comparators {6b}

We are using the same treatment protocol as our pilot
study. However, we have changed the comparator group
design. The intervention for the control group (CP) is subthreshold electrical stimulation. We apply transcutaneous
electrical nerve stimulation (TENS) to the volar aspect of

the paretic arm for 15 min. The current is an asymmetrical biphasic square impulse waveform with a frequency of
40 Hz and a pulse width of 250 μs. The intensity is initially
adjusted so that the subjects perceive the stimulation. It is
then reduced to 1 milliamp (sub-sensory threshold) and
maintained for 15 min. Consistent with our pilot study, we
expect improvement in both groups. However, we expect a
larger magnitude of improvement in the BMP group that
will be most evident at follow-up.
Both groups participate in a different priming intervention but the same TST protocol. The difference between
the comparators is the priming intervention. The choice
of the subthreshold e-stim control group was to control
for participant’s expectations and attention such that any
difference between the two groups is due to BMP.
Intervention description {11a}

There are fifteen, 2-h sessions of treatment over 5 weeks
(approximately three times per week) for a total of 30 h of
BMP + TST in the experimental group. The control group
receives the same duration and schedule (30 h of CP +
TST) for treatment. A sixth week is reserved for any makeup sessions needed. There are two, 1-h treatment sessions
per study visit. A minimum 30-min break separates each
hour of training. During the first session, participants
receive 15 min of priming (either BMP or CP) followed by
45 min of therapist-selected activities from the TST protocol. The second hour includes 15 min of priming plus 45
min of training on tasks selected from the Canadian Occupational Therapy Measure (COPM) [22].

Stoykov et al. Trials

(2022) 23:523

Priming

Priming precedes treatment in both intervention groups.
During BMP, participants use the Exsurgo priming device
(Exsurgo Bilateral Primer, Aukland, New Zealand) (see
Fig. 1). For the participants assigned to the BMP group,
both hands are strapped in place in the vertically oriented
plates which are attached via a mechanical linkage. Both
wrists move in rhythmic, symmetrical wrist flexion and
extension for 15 min at a target frequency of 1 Hz as cued
by a metronome. Participants do not need to have active
flexion and extension of the affected hand because the
less affected arm drives the movement of the paretic UE
(through the mechanical linkage underneath the surface
of the device). The device has a counter to keep track of
repetitions with an ideal goal of 900 repetitions per 15
min of priming. The optimal daily (inclusive of both sessions) goal of priming repetitions is 1800. Participants are
encouraged to strive to meet the goal.
TST treatment

The first session includes tasks from a TST protocol that
has been used and shown efficacy in previous clinical trials [13, 23–26]. The TST protocol includes both unimanual activities and bimanual activities. Tasks are designed
to improve components of upper extremity control such
as transport, grasp, grip, release, and manipulation. The
therapist selects 3–4 activities or exercises from the TST
protocol based on the specific needs of the participant.
The specific activities and number of repetitions are
recorded. Emphasis is placed on increasing repetitions as
client ability and task difficulty allow.
The second of the two daily sessions includes practice
in two or more activities identified by the participants
as both meaningful to them and needing improvement.
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The Canadian Occupational Performance Measure
(COPM) [22] is administered at the baseline assessment
appointment and is used to guide treatment. The activities of daily living (ADL) skills must have an UE component to them and can be unimanual (i.e., brushing hair)
or bimanual (i.e., stirring a cake mix). Both Sainburg
and colleagues [27] and Kantak et al [28] have stressed
the importance of using bimanual asymmetric tasks in
stroke rehabilitation. These tasks are often used during
performance of ADL. During bimanual task training, the
affected arm can either be used as a stabilizer (i.e., the
arm holding the bowl) or as the dominant manipulator
(i.e., the affected arm performing the mixing). The level
of use of the affected arm (i.e., stabilizer or manipulator) is determined by goals of the participant, ability of
the affected arm, demands of the task, and pre-morbid
hand dominance. Activities are graded by the clinician
to achieve a “just right” challenge, and emphasis is placed
on increasing repetitions as participant ability and task
difficulty allow. The specific tasks and the number of repetitions are recorded.
Home program

At the end of the first treatment day, therapists issue participants instructions for completing a set of active movements outside of therapy. Participants are given three
sets of upper extremity movements targeting stretching,
range of motion, and/or muscle strengthening. Targeted
muscle groups depend on individual needs as determined
by the therapist (i.e., wrist flexion, extension, and radial/
ulnar deviation; forearm pronation and supination; elbow
flexion and extension; digit extension, flexion, abduction, and adduction; shoulder flexion, extension, abduction, internal rotation, and external rotation). Therapists
instruct participants to complete these specified movements 10–15 min daily. A handout with instructions is
provided to ensure carryover.
Therapist training

Fig. 1 “Rocker” for bilateral priming. Legend: The Exsurgo priming
device (Exsurgo Bilateral Primer, Auckland, New Zealand) used for
bilateral priming in this protocol. Permission to use this image was
granted by Exsurgo Rehabilitation Ltd. (see Additional file 3)

All treatment therapists are trained in the administration of priming and TST protocols by the author of the
protocol (MES). Subsequently, therapists must complete
a formal standardization process that consists of the
therapist(s) participating in a mock treatment session
with a person with stroke. In order to pass the standardization, the therapists must score 90% on an itemized
standardization checklist. Items on the checklist include
the following: (1) grades activity to provide just right
challenge; (2) able to downgrade activity when necessary;
and (3) adapts environment to optimize performance.
Therapists must pass a re-standardization test every 6
months. When needed, therapists meet with the investigator in charge of treatment fidelity to review videos and
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discuss treatment plans, treatment goals, and the progress of therapy.

outcome measures at pre-intervention, post-intervention, and 8-week follow-up.

Criteria for discontinuing or modifying allocated
interventions {11b}

Primary outcome measure: Fugl‑Meyer Upper Extremity Test
(FMUE)

Participation in this study can be terminated by the
investigator without participant consent if circumstances
arise that warrant doing so. This would include injury
that would limit participation in treatment or testing or if
the person becomes ill during the research study. A decision would be made to protect the health and safety of
the participant. Participants may also voluntarily withdraw from the treatment at any time point. If continuing with evaluations is not harmful to the participant,
we request that they complete post-evaluation and/or
8-week follow-up evaluation.

The primary outcome measurement is the FMUE, an
impairment scale with established interrater and intrarater reliability that addresses both synergy and isolated
movements of the upper limb [12, 29, 30]. It comprises
nine subscales that include reflex activity, dynamic movement within flexor synergy, dynamic movement within
extensor synergy, movements mixing flexor and extensor
synergies, movements out of synergy, normal reflex activity, wrist stability and mobility, hand, and coordination/
speed subscales. The total score ranges from 0 to 66. The
pre-intervention to follow-up change score (follow-up –
pre) was selected because previous priming-plus-training studies have documented that the largest difference
between groups occurs at follow-up [13, 16, 18].

Strategies to improve adherence to interventions {11c}

Adherence to the interventions has three components.
This includes attendance to scheduled appointments,
completing the assigned priming for 15 min per session, and completing a sufficient number of repetitions
per session in the TST protocol. Although the ability to
perform repetitions varies among participants, we expect
that participants should reach a minimum of 100 repetitions of TST over 90 min of treatment. Treatment therapists continuously remind participants of this goal.
Regarding attendance, all participants receive a hard copy
of their treatment schedule to promote adherence. If a participant is having difficulty keeping track of the sessions,
reminder phone calls to the participant or the participant’s
significant other or next of kin is initiated. We consider a
participant 100% adherent for attendance if they complete
the total of 30 h priming and training within 6 weeks.
Relevant concomitant care permitted or prohibited
during the trial {11d}

Participants are not permitted to be in occupational therapy treatment during the study and cannot be involved in
any other physical rehabilitation studies.
Provisions for post‑trial care {30}

If participants require any care during or after their participation in this trial, the study team will follow the policies of the Shirley Ryan AblityLab and the Northwestern
PTHMS Department. We do not expect greater than
minimal harm from trial participation. If harm should
arise, whether related to research protocol or not, we do
not offer any compensation.
Outcomes {12}

Each participant is evaluated with primary and secondary outcome measures, TMS measures, and additional

Secondary outcome measure: Chedoke Arm & Hand Activity
Index 9 (CAHAI‑9)

The secondary outcome measure, the CAHAI-9, is a
bimanual function test. It has strong support for its
cross-sectional validity, test-retest reliability, and sensitivity to change [31, 32]. The CAHAI-9 was chosen
because, in individuals with severe UE hemiparesis,
use of the affected hand most often occurs in bimanual
tasks. CAHAI-9 involves nine activities including opening a jar, pouring water, drawing a line with a ruler, buttoning a shirt, using the telephone, wringing out a wash
cloth, applying toothpaste to a tooth brush, cutting food,
and drying one’s back with a bath towel. The scale range
is from 1 to 7 for each test item (each bilateral activity).
The test items are graded by the amount of use of the
affected hand. The affected hand can be used as a stabilizer or manipulative and is not graded down if used in
a stabilizer role. The change score from pre-intervention
to follow-up (follow-up–pre) will be analyzed as previous
priming studies have documented the largest difference
between groups occurs at follow-up [13].
Transcallosal inhibition

The primary TMS measure documenting possible neurophysiological change is transcallosal inhibition (TCI)
from the ipsilesional to the contralesional hemisphere.
TCI is collected via the ipsilateral silent period (iSP)
using single-pulse TMS. Muscle activity is recorded from
the extensor carpi radialis (ECR) of the affected and less
affected forearms with surface EMG. Data is recorded for
analysis using Signal 6. Magnetic stimuli are delivered
using the MagStim 200 and a focal figure-of-eight coil
(wing diameter 9 cm).
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To begin, the participant is seated in a chair with their
arms supported in a resting, pronated position. The optimal coil position for eliciting motor evoked potentials
(MEPs) for the ECR is determined first for the contralesional hemisphere and subsequently for the ipsilesional
hemisphere. Following hot spotting, the resting motor
threshold (RMT) is obtained by increasing or decreasing
stimulator output to find the minimal intensity at which
4 out of 8 resting MEPs with a peak-to-peak amplitude of
50 microvolts can be elicited.
For those without MEPs on the paretic side, coil location of the contralesional hemisphere is mirrored. If we
cannot obtain resting MEPs from ipsilesional hemisphere, we attempt to elicit active MEPs (during active
movement) using the criteria documented by Stinear
et al. [33]. The elicitation of active MEPs determines the
MEP status of participants who are subsequently documented as either MEP(+) or MEP(−). MEP status is a
biomarker, and it is widely believed that individuals who
are MEP+ have better chance of improvement. Documenting MEP status in a clinical trial is considered best
practice [34].
During the experiment to elicit an iSP, both hands
of the participant remain positioned in pronation, and
participants are instructed to extend the wrist ipsilateral to the stimulated hemisphere and generate a voluntary contraction of 50% of the averaged maximum
voluntary effort. Real-time, computerized visual feedback is provided to assist participants in the accuracy of
maintaining effort at 50%. Meanwhile, 16 stimuli (one
stimulation every 5 s or .2 Hz) are delivered over the
ECR hotspot at 150% RMT or 80% maximum stimulator output (MS), whichever is greatest. If RMT in the
ipsilesional hemisphere cannot be obtained, the participant receives stimulation at 100% MSO. Rest breaks of
approximately 30 s are given every 4 stimuli to prevent
fatigue. The stimulation procedure is repeated for the
contralesional hemisphere.
Additional outcome measures: Action Research Arm Test
(ARAT)

The ARAT is a test of unilateral function and includes
grasp, grip, pinch, and whole arm movement subscales
[35]. Total scores range from 0 to 57. The ARAT is
often used in post-stroke rehabilitation studies as a primary outcome measure [36–38] or secondary outcome
measure [39]. As such, we have included it as an additional outcome measure. We predict that if changes are
observed, they will be more evident in our higher strata
(individuals with FMUE scores between 30 and 38) at the
follow-up time point.
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Grip termination time (GTT) and maximal grip strength

The GTT measures the time it takes for an individual to
release an object and is administered following the methodology previously published [40]. Both the affected and
less affected hand are evaluated. Electrodes are placed
over the flexor digitorum superficialis (FDS) as well as
extensor digitorum communis (EDC) of both forearms
following standard skin preparation techniques. Maximal voluntary activation of each muscle as well as muscle activation onset time and offset time, indicated to the
participant by an auditory cue, is recorded. Maximal grip
strength is also documented from a hand dynamometer.
Neuro‑QoL

The Neuro-QoL is a self-report measure that assesses
patient experience of neurological conditions and treatment for such conditions through quality-of-life domains
including mental, social, and physical health [41]. The
instrument has high reliability and established internal
consistency and is self-administered via Research Electronic Data Capture (REDCap) survey. Neuro-QOL is a
Common Data Element (CDE) measures, which are population-specific measures either strongly recommended
or required. CDE measures enable clinical investigators
to systematically collect, analyze, and share data across
the research community.
Participant timeline {13}

The duration of an individual’s participation in the
study is approximately 4–6 months. The schedule of
enrollment, assessment, and intervention is depicted
in Fig. 2. Figure 3 presents an outline of an individual’s
visit schedule including the type of visit (evaluation or
treatment) and the number of hours per session. Once
the individual completes baseline evaluations, treatment
begins in the same or following week. We allow 6 weeks
for treatment (5 weeks with an additional week for
missed sessions). The primary investigator determines if
an extension for treatment beyond 6 weeks is allowed for
a particular participant.
Sample size {14}

We are enrolling 38 subjects per group (N = 76). Allowing for the attrition of 12 participants (15% based on our
pilot study [13]), we project at least 32 subjects per group
will have both the baseline and follow-up data required
to compute our change outcomes at 8 weeks post-treatment cessation. For the hypotheses tested for objectives
1 and 2, we will evaluate between-group (BMP+TST
vs. CP+TST) differences using analyses of covariance (ANCOVA) that adjust for the outcome measure
at baseline; tests will be two-sided at the 5% level (α =
0.05). The power of these tests depends on the number of
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Fig. 2 Schedule of enrollment, interventions, and assessments. Legend: Participants who are eligible are enrolled, participate in baseline
assessments, are allocated to treatment group, and receive 5 weeks of intervention with the 6th week used to make up for any missed sessions. The
post-treatment assessments occur between weeks 6 and 7 and follow-up assessments occur between weeks 13 and 15.

Fig. 3 Schedule of visits and time per visit. Legend: Participants complete up to 24 visits over 15 weeks, with sessions lasting from 2 to 3 h each. The
schedule for visits during the intervention phase will consist of 1 h of priming + task-specific training, then a break of at least 30 min, followed by
another 1 h of priming + task-specific training

participants in each group, the separation of the means of
each group, the significance level, the population standard deviation (SD) of the outcome measures, and the correlation between measures at baseline and follow-up. We
consider what sample size per group (n) will provide 90%
or greater power.
We discuss each of the two objectives in turn. Table 2
presents the primary outcome measure (FMUE), secondary outcome measure (CAHAI-9), and the additional
outcome measure (TCI in objective 2). For each measure, the table shows the difference in the group means

Table 2 Sample size analysis: primary and secondary measures
Mean difference

SD

Aim 1
FMUE

5.98

8.11

CAHAI-9

5.34

7.26

2.74

3.71

Aim 2
TCI

Effects detectable with 90% power for Aims 1 and 2
Abbreviations: SD standard deviation of the change score (follow-up–pre), FMUE
Fugl-Meyer Upper Extremity Function, CAHAI-9 Chedoke Arm & Hand Activity
Index-Nine, TCI transcallosal inhibition

Stoykov et al. Trials

(2022) 23:523

that can be detected with 90% power assuming N=32
per group, along with the hypothesized SD of the outcome. Power computations assume a modest correlation
between baseline and follow-up for measures of R2 = 0.2.
To derive our estimates of the SD of outcome measures
at follow-up (8 weeks post-treatment cessation), we used
the results of a published pilot study at 6 weeks posttreatment cessation [13].
Recruitment {22}

Participants are recruited from the Northwestern University and Shirley Ryan AbilityLab Clinical Research Registry, a registry that identifies individuals who consent to be
contacted for research purposes post-stroke. The Clinical Research Registry began in 2001 and has compiled the
information of over 776 individuals post-stroke, including
names, contact information, and clinical characteristics
(e.g., side of lesion, date of stroke, level of arm impairment).
Other recruitment methods include reaching out to
stroke support groups in the Chicago area connected
with neurologists in nearby medical centers (i.e., Northwestern University, University of Illinois, and University
of Chicago). We also post IRB-approved flyers in the
community. Referrals are accepted through doctors and
therapists. Potential participants can also contact the
investigators independently.

Assignment of interventions: allocation
Sequence generation {16a}

Prior to randomization, participants are stratified
according to the FMUE measured at baseline. Participants with a FMUE score of 23 through 29 are stratified
to the severely impaired group, and those with scores of
30 through 38 are stratified into the moderately impaired
group. Each impairment stratum has its own computergenerated random number list. Since participants are
stratified, we plan to conduct exploratory analyses on the
extent to which the severity of impairment alters treatment outcome.
Concealment mechanism {16b}

To ensure concealment, a research assistant records
randomization assignment in a password-protected
document and communicates the participant’s priming
assignment via data recording sheets kept in a locked
cabinet inaccessible to masked individuals.
Implementation {16c}

Once the participant completes baseline evaluations,
FMUE scores are communicated to the study coordinator
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who assists with allocation. The study coordinator contacts a specific member of the investigative team with
the following information: (1) FMUE category (severe
or moderate) and (2) number of the randomized participant. This investigator holds the randomized computergenerated lists for both stratification levels and allocates
group assignment. The investigator has limited contact
with study participants and is not involved in the dayto-day aspects of the treatment or evaluation. The study
coordinator then communicates group assignment to the
occupational therapists on the team.

Assignment of interventions: masking
Who will be masked {17a}

Members of the investigative team including therapists
administering motor assessments and individuals collecting, processing, and analyzing the TMS data are
masked to treatment allocation. Treatment therapists
and the participants are not masked for practical reasons. All evaluations occur in a different space than
treatment. Participants are reminded not to discuss
group assignment or treatment with any individual
administering assessments.
Procedure for unmasking if needed {17b}

The only circumstance under which unmasking is permissible is in the case of a participant experiencing a
serious adverse event. In this case, only the medical
safety monitor for the trial is informed of the allocation
to intervention during the trial. The unmasking procedure will not include any study staff member or member of the investigative team who is masked.

Data collection and management
Plans for assessment and collection of outcomes {18a}

Behavioral assessments, TMS measures, and grip termination time (GTT) are collected for all participants
at baseline, post-treatment evaluation, and an 8-week
follow-up evaluation. All raters must pass a standardization test with a score of 95% to insure proper assessment
administration. Procedures are followed according to
published directions [12]. Subsequent standardizations
occur every 6 months. Staff members administering GTT
and TMS are thoroughly trained in all procedures.
Plans to promote participant retention and complete
follow‑up {18b}

If a participant misses scheduled appointments more
than one time, the therapist(s) speaks to the participant about the necessity of showing up for appointments and participating in the intervention. If this does
not produce a change in behavior, the investigator then
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speaks with the participant and emphasizes the importance of consistent attendance. Individuals who have
difficulty remembering appointments receive regular
phone calls. They are also contacted prior to the 8-week
follow-up appointment.
Data management {19}

Completed de-identified data sheets as well as consents with
protected health information are signed by the study staff
member, and the recorded data is scanned to a web-based
data system that is password protected. Data is backed up
on the web-based system as well as computer hard drives.
Data from the behavioral assessments are entered into
REDCap by selected study staff. TMS data is collected and
stored on a primary lab computer hard drive and backed up
on an external hard drive at regular intervals.
The first level of monitoring is carried out by the study
coordinator and includes checking all informed consents,
evaluations, and treatment records. All errors are reviewed,
and the coordinator verifies that errors are crossed out and
annotated with the researcher’s signature and date in the
hard copy of data sheets. The study may also be monitored
by a pre-arranged visit from a representative of the sponsor’s IRB office. Specific participant files that may be in an
audit include consent forms, consent process forms, and
evaluation forms. Delegation of authority logs and other
items from the regulatory binder are also examined.
Confidentiality {27}

Hard copies of screens containing demographic and protected health information are stored in locked files accessible to the study coordinator. Hard copies are also scanned
into a server protected by a firewall from Northwestern University. Selected study members have access to the server.
De-identified demographics are stored in REDCap. A limited number of study personnel (including study staff that
perform screenings or are involved in the consent process)
have access to REDCap. De-identified data will be shared
with the sponsoring agency if requested. The investigative
team is responsible for receipt and transmission of the data.
No information about participants or provided by
the participants during the research will be disclosed
to others without their written permission, except (1) if
necessary to protect participant’s rights or welfare (for
example, if they are injured and need emergency care
or when the Institutional Review Board monitors the
research or consent process); or (2) if required by law.
Plans for collection, laboratory evaluation, and storage
of biological specimens for genetic or molecular analysis
in this trial/future use {33}

See above 26b, there will be no biological specimens
collected.
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Statistical methods
Statistical methods for primary and secondary outcomes
{20a}

Data will be stored in SAS data files and statistical analyses will be conducted using SAS. We will use an intent-totreat analysis for our primary and secondary analyses. At
baseline, post-intervention, and 8-week follow-up time
points, standard descriptive statistics will be calculated
for degree of impairment (FMUE) and degree of function
(CAHAI-9). We will also compute standard descriptive
statistics for less severely impaired participants (FMUE
30-38) and the more severely impaired participants
(FMUE 23-29) as determined at baseline. We will assess
the relationship between both FMUE and CAHAI-9 at
baseline and time since stroke, age, and gender. In addition, we will examine the correlation between changes
in FMUE and CAHAI-9 from baseline to follow-up time
points (end of intervention and 8 weeks post-treatment
cessation) and time since stroke, age, and gender. We will
report pairwise correlations and standard errors for these
descriptive analyses.
Confirmatory analyses will largely use normal theory
methods based on analysis of covariance. We will use
residual diagnostics to evaluate model fit and take appropriate data transformations as necessary.
Hypothesis 1a and 1b analysis

For each dependent measure (FMUE and CAHAI-9),
primary confirmatory analyses will compare the experimental group (BMP+TST) versus the control group
(CP+TST). We will use normal linear models with effects
for treatment assignment and the outcome measure at
baseline, equivalent to an analysis of covariance. We will
report point estimates and standard errors of these differences and conduct two-sided null hypothesis tests at
the 5% level (α = 0.05).
Hypothesis 2a and 2b analysis

Descriptive statistics for Hypotheses 2a and 2b will follow a similar approach as those for 1a and 1b, but we
will focus on TCI as our outcome of interest. Confirmatory analyses will analyze differences in TCI between
treatment arms at 8 weeks post-treatment cessation.
We will report estimated differences between treatment
arms along with standard errors. We will also conduct
two-sided hypothesis tests at the 5% level. For 2b, we
will perform a correlation to determine the relationship
between changes in ipsilesional TCI and FMUE from pre
to follow-up.
Interim analyses {21b}

Not applicable. At this time, we have no plans for an
interim analysis.
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Methods for additional analyses (e.g., subgroup analyses)
{20b}

Composition of the data monitoring committee, its role
and reporting structure {21a}

As exploratory analyses, we will use linear regression
models outcomes at 8 weeks post-treatment cessation
as the dependent variable (FMUE, CAHAI-9, and TCI).
These models will include treatment assignment (BMP
vs. CP) and baseline outcome measure as a fixed-effects,
as well as patient characteristics (age, low or high impairment severity at baseline, sex, and MEP status). We will
examine differential impacts by fitting separate models
with treatment-impairment severity, treatment-sex, and
treatment-MEP status interactions. We will report relevant point estimates and standard errors for these models and conduct 5% level tests for interaction terms with
two-sided alternative hypotheses.

We have established a data safety and monitoring board
(DSMB) that consists of international experts in therapeutic interventions as well as TMS with the post-stroke
population. They provide a mechanism to assure monitoring of the overall conduct of the study (including
issues with safety, ethics, patient recruitment and accrual,
retention, and adequacy of study design to achieve the
specific aims). They provide feedback to the study team
for the possible protocol amendments. The DSMB also
reviews serious adverse events (SAEs) and adverse events
(AEs) and are alerted to any interim concerns. The DSMB
is independent of the study sponsor and have no competing interests.

Methods in analysis to handle protocol non‑adherence
and any statistical methods to handle missing data {20c}

Adverse event reporting and harms {22}

We will measure protocol adherence by the median
number of repetitions of TST repetitions. Treatment
therapists record the number of repetitions for each
activity, and the data is de-identified and transferred
to an excel sheet. Participants will be labeled as adherent if the median number of daily TST repetitions (over
the 2-h visit) is equal to or greater than 100. Information about treatment activities is only available to nonblinded individuals.
Though we plan to follow up with patients repeatedly
to minimize the amount of missing data, we expect some
data may still wind up missing. Should greater than 5%
of data be missing, we will explore missingness patterns
via graphical analyses to evaluate potential mechanisms
of missingness. If appropriate, multiple imputation will
be used to handle missing data.
Plans to give access to the full protocol, participant‑level
data, and statistical code {31c}

Access to the full protocol and participant-level data will
be considered upon submission of a reasonable request.

Oversight and monitoring
Composition of the coordinating center and trial steering
committee {5d}

The implementation of the trial is overseen and monitored by the trial steering committee. The trial steering committee is composed of the principal investigator
[DMC] who is ultimately responsible for the trial, the
co-investigator [MES], study coordinator [AW], and the
experimentalist [EK]. All members of this committee
are responsible for recruitment and retention activities.
Select research staff are involved in the consent process
and must be identified as such in the IRB study protocol.

Safety events are reported by the participant or observed
by the research staff. Events are relayed to the PI and the
safety monitor to determine next steps and if there is a
possible relationship to the event and the research protocol. All events are documented and stored in a specific
file on the firewall-protected server. The safety monitor,
an MD, determines whether the event is categorized as
an AE or an SAE, and oversees any notifications to the
Northwestern University IRB. Review of all safety data
occurs at every DSMB meeting. The DSMB report is
signed by the PI and the Safety Monitor. It is filed with
the IRB during annual continuing review. Data reviewed
includes SAEs, AEs, and unusual changes in behavioral
and TMS measures.
Frequency and plans for auditing trial conduct {23}

Northwestern University IRB monitors the conduct of all
clinical trials. The Northwestern IRB conducted a postapproval monitoring visit during the second year of the
trial. The study team prepared items using a checklist
provided by the IRB including a Post Approval Monitoring Checklist, Clinical Trial Checklist, and the Participant File Checklists for a selected number of participants.
On-line and hard copies of participant files are reviewed
at monitoring visits. The IRB notified the study team of
minor findings in the study documentation that needed
attention (i.e., form completion). The study team replied
to the report and documented how the findings would be
addressed going forward.
Plans for communicating important protocol amendments
to relevant parties (e.g., trial participants, ethical
committees) {25}

Protocol amendments are communicated to and
approved by the Northwestern University IRB. All study
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staff receive notice of changes deemed appropriate by
study coordinator.
Dissemination plans {31a}

The investigative team plans to publish trial results in
peer-reviewed journals emphasizing neurorehabilitation.
We will also present the trial results at neuroscience and
rehabilitation science conferences.

Discussion
This is the first large-scale, randomized clinical trial to
evaluate the effect of bilateral priming and a systematic
task-specific training protocol in moderate to severe
chronic upper limb hemiparesis. The effect of training
is rigorously controlled by using the same TST protocol
in both experimental and control groups. The control
protocol is dose matched in time with the experimental
bilateral priming and is provided to satisfy participant
attention and expectations.
This trial addresses a need in the field of neurorehabilitation to find effective, easily accessible treatments
for participants post-stroke who have lower prospects
for motor recovery due to moderate to severe UE impairment. These patients make up 75% of all stroke survivors
who currently have no access to interventions likely to
result in clinically significant improvements in motor
function. For example, participants with chronic UE
impairment made only modest improvements in FMUE
scores after completing intervention programs using
different variations of robotic therapy [4, 42]. Mirror
therapy has been used in post-stroke participants with
a range of impairment levels [43, 44]. However, nonresponse to mirror therapy is frequent and is related to
lesion location [45] and initial impairment level [46]. In
contrast, our previous findings and the findings of others indicate that bilateral priming may provide consistent
clinically significant improvements in post-stroke hemiparesis [11, 13, 18].
Enrollment for this trial is ongoing at the time of
publication. Analysis will occur when all participants
complete the trial. Consistent with our previous studies, we expect an improvement in arm function in
both the experimental and control group. We expect
differences in improvement to be most evident at the
follow-up time point. A positive outcome of this trial
will emphasize the role of bilateral priming in rehabilitative training. Based on previous results of priming
with rehabilitation protocols, such as video game-based
movement therapy [11] or home programs emphasizing fine motor control [18], we expect that BMP will be
applicable to many forms of post-stroke motor training
other than task-specific therapy.
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We expect the BUMP trial to demonstrate the additive effect of bilateral priming on our task-specific
training therapy. However, we are aware that previous
large trials for upper limb hemiparesis post-stroke have
failed to detect significant between-group differences
[4, 47, 48] and, in some cases, pre-/post-intervention
effects have been small [36]. We expect the magnitude
of change in the BMP+TST group to be greater than
the change in the CP+TST. We may also demonstrate
a large pre-/post-improvement on a more chronic poststroke population. As previously stated, Ward and
colleagues demonstrated a large improvement in the
FMUE following 90 h of various types of upper limb
therapy techniques [3]. We expect our improvement to
be comparable to the Ward study. However, we expect
similar improvements with only 30 h of intervention,
one third of the dosage time used in the study by Ward
and colleagues [3].
Trial status

At the time of this publication submittal, we are recruiting participants with projected completion in June of
2023. This is protocol version 14. Recruitment began February 1, 2017.
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